ZIMMER BIOMET (ZBH) Asia Pacific president sells 5,000 shares in open market

Rhea-AI Filing Summary

ZIMMER BIOMET HOLDINGS, INC. executive Yi Sang, Group President, Asia Pacific, reported selling a total of 5,000 shares of Common Stock in open-market transactions on May 29, 2026 at prices around $82.65 per share. After these sales, he continues to hold a substantial direct position of over 27,000 shares.

Insider Trade Summary

Net Seller: 5,000 shares ($413,216)

Net Sell 2 txns

Insider Yi Sang

Role Group President, Asia Pacific

Sold 5,000 shs ($413K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,200	$82.64	$347K
Sale	Common Stock	800	$82.66	$66K

Holdings After Transaction: Common Stock — 28,051 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold (total): 5,000 shares First trade size: 800 shares Second trade size: 4,200 shares +3 more

6 metrics

Shares sold (total) 5,000 shares Open-market sales on May 29, 2026

First trade size 800 shares Common Stock sale at $82.66 per share

Second trade size 4,200 shares Common Stock sale at $82.64 per share

Sale price (first trade) $82.66/share Open-market sale of 800 Common Stock shares

Sale price (second trade) $82.64/share Open-market sale of 4,200 Common Stock shares

Direct holdings after transactions Over 27,000 shares Common Stock held directly after May 29, 2026 sales

Key Terms

Form 4, open-market sale, Common Stock, transaction code S, +1 more

5 terms

Form 4 regulatory

"were disclosed in a Form 4 insider filing with the SEC"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"reported selling a total of 5,000 shares of Common Stock in open-market transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"sold 5,000 shares of Common Stock in open-market transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code S regulatory

"transactions were categorized as open-market sales under SEC transaction code S"

Group President, Asia Pacific other

"executive Yi Sang, Group President, Asia Pacific, reported selling"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Sang

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW INDIANA 46580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group President, Asia Pacific

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		S		4,200	D	$82.64	28,051	D
Common Stock	05/29/2026		S		800	D	$82.66	27,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Sang Yi (power of attorney previously filed)	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ZIMMER BIOMET (ZBH) report for Yi Sang?

ZIMMER BIOMET reported that executive Yi Sang sold 5,000 shares of Common Stock in open-market transactions. The sales occurred on May 29, 2026, and were disclosed in a Form 4 insider filing with the SEC covering his direct ownership position.

How many ZIMMER BIOMET (ZBH) shares did Yi Sang sell and at what prices?

Yi Sang sold 5,000 ZIMMER BIOMET Common Stock shares in two trades: 800 shares at $82.66 and 4,200 shares at $82.64 per share. Both transactions were categorized as open-market sales under SEC transaction code S.

What is Yi Sang’s remaining ZIMMER BIOMET (ZBH) shareholding after the sale?

Following the May 29, 2026 transactions, the Form 4 shows that Yi Sang continues to hold more than 27,000 ZIMMER BIOMET Common Stock shares directly. This indicates he retained a significant ongoing equity stake after completing the 5,000-share sale.

Was the ZIMMER BIOMET (ZBH) insider sale by Yi Sang a buy or sell transaction?

The filing classifies both transactions as sales. They are coded with transaction code S, described as open-market or private sales, and the normalized transaction_direction field marks them clearly as sell transactions rather than purchases or derivative exercises.

Did Yi Sang’s ZIMMER BIOMET (ZBH) Form 4 include any option exercises or derivatives?

The Form 4 reflects only non-derivative Common Stock sales. The derivativeSummary section is empty and transaction codes are S, indicating no option exercises, conversions, or other derivative transactions were reported alongside these open-market stock sales.